LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Superficial Bladder Cancer · Non-muscle Invasive Bladder Cancer With Carcinoma in Situ · Non-muscle Invasive Bladder Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.9
Announced layoffs or restructuring
Since Jun 18, 2026 · was worth 15, fading over time
- +2.8
A key executive is leaving
Since Jun 15, 2026 · was worth 15, fading over time
- +2.8
Announced layoffs or restructuring
Since Jun 15, 2026 · was worth 15, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 350 (planned)
- Started
- Apr 22, 2021
- Main results expected
- Apr 30, 2028
- Fully finished
- Oct 30, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Nature, incidence, relatedness, and severity of all AEs and SAEs according to the CTCAE v5.0.
Measured over: Approximately 2 years
Phase 2: Percentage of patients with cystoscopic CR at any time, based on exam, urine cytology and appropriate biopsies.
Measured over: Approximately 24 weeks
Phase 2: Nature, incidence, relatedness, and severity of treatment emergent adverse events (as assessed by CTCAE v5.0)
Measured over: Approximately 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- layoffs: base 15, now 2.9, since 2026-06-18, fades (half-life) · source filing
- key_exec_departure: base 15, now 2.8, since 2026-06-15, fades (half-life) · source filing
- layoffs: base 15, now 2.8, since 2026-06-15, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT04752722 · record last updated 2026-08-07 · checked 2026-11-09 15:47 UTC